Associations Between Model-Predicted Rivaroxaban Ex Characteristics and Efficacy and Safety Outcomes in the Thromboembolism

Journal of Thrombosis and Thrombolysis

50, 12-19

DOI: 10.1007/s11239-020-02078-8

Citation Report

#	Article	IF	Citations
1	2021 Update of the International Council for Standardization in Haematology Recommendations for Laboratory Measurement of Direct Oral Anticoagulants. Thrombosis and Haemostasis, 2021, 121, 1008-1020.	4.6	206
2	Recommendations From the ICM-VTE: General. Journal of Bone and Joint Surgery - Series A, 2022, 104, 4.	4.1	33
3	Evaluating Pharmacokinetic Drug–Drug Interactions of Direct Oral Anticoagulants in Patients With Renal Dysfunction. Expert Opinion on Drug Metabolism and Toxicology, 2022, 18, 189-202.	4.8	6
4	Is a Lower Dose of Rivaroxaban Required for Asians? A Systematic Review of a Population Pharmacokinetics and Pharmacodynamics Analysis of Rivaroxaban. Pharmaceutics, 2023, 15, 588.	7.5	25
5	Poor Correlation of Rivaroxaban Concentration With the Routine Coagulation Screening Test in Chinese Patients With Atrial Fibrillation. Journal of Clinical Pharmacy and Therapeutics, 2023, .	1.0	1
6	An Extension of Biorelevant Fed-State Dissolution Tests to Clinical Pharmacokinetics – A Study on Gastrointestinal Factors Influencing Rivaroxaban Exposure and Efficacy in Atrial Fibrillation Patients. International Journal of Pharmaceutics, 2024, 649, 123626.	6.1	8
7	Direct Factor Xa Inhibitors Versus Low Molecular Weight Heparins or Vitamin K Antagonists for Prevention of Venous Thromboembolism in Elective Primary Hip or Knee Replacement or Hip Fracture Repair. Cochrane Database of Systematic Reviews, 2025, 1, CD011762.	6.9	6
8	Rethinking Thromboprophylaxis Duration After Total Joint Arthroplasty: When Historical Evidence Meets Modern Surgical Practice. Journal of Thrombosis and Thrombolysis, 2026, 59, 1-4.	2.2	1
9	No Relevant Pharmacokinetic Interaction Between the KRAS G12C Inhibitor Sotorasib and the Direct Oral Anticoagulant Rivaroxaban in Healthy Subjects. International Journal of Cancer, 2026, 158, 2920-2927.	5.0	0